Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NetEnt intends to accelerate payment of earn-out consideration for Red Tiger through a directed issue of new shares

NetEnt continues to increase productivity and strengthen its competitiveness, and the integration of Red Tiger is an important part of this process. To support and speed up the integration, NetEnt intends to accelerate the payment of the earn-out consideration for Red Tiger through a directed issue of B-shares to the sellers of Red Tiger.NetEnt acquired Red Tiger in September 2019. In conjunction with the acquisition, it was announced that an additional consideration amounting to maximum GBP 23 million could become payable in 2022 on an earn-out basis, subject to Red Tiger’s financial

NetEnt integrates Red Tiger to realize further synergies

To further strengthen competitiveness and increase efficiency NetEnt is implementing changes in the organization and a full integration with recently acquired Red Tiger. The changes mean a reduction in the workforce by approximately 120 employees, mainly in Stockholm.NetEnt has previously communicated its ambition to integration further with Red Tiger, which was acquired in September of 2019. The acquisition has exceeded expectations and offers significant potential synergies, increased efficiency and economies of scale. A restructuring is now being implemented to speed up the full

Detection Technology’s annual review, financial statements and CG statement 2019 published

Detection Technology Plc company announcement 24 March 2020 at 10:00 (EET) Detection Technology’s annual review, financial statements and CG statement 2019 published Detection Technology Plc’s annual review and financial statements 2019 have been published. The reports are available on the company’s website (www.deetee.com/investors) and attached to this release. The annual review and the financial statements are available in Finnish and English. Today, Detection Technology has also published its Corporate Governance Statement for 2019. The CG Statement is available in English at

HiQ withdraws proposal of a share split and share redemption procedure

The Board of Directors of HiQ International AB has decided to withdraw the previously communicated proposal to the Annual General Meeting 2020 regarding a share split and share redemption procedure of SEK 3.40 per share.As a consequence of the global outbreak of COVID-19 the Board of Directors prioritizes to maintain the company’s strong financial position – and to create freedom of action in the changed market situation.   This information is information that HiQ International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for

Bambuser enters into strategic collaboration with Centra

Bambuser has entered into a strategic collaboration with the e-commerce platform Centra to offer Live Video Shopping to Centra’s global Direct-to-Consumer brands. The collaboration includes a solid integration that allows Centra's customers to seamlessly become customers of Bambuser.Centra (centra.com) is a Swedish e-commerce platform targeting global, Direct-to-Consumer fashion and lifestyle brands. Centra’s customers include established brands such as iDeal of Sweden, Soft Goat, Nudie Jeans and Douchebags. As of today, Bambuser and Centra have entered into a collaboration to offer Live

SOTKAMO SILVER AB: CHANGES IN THE BOARD

Press release: Stockholm, March 24, 2020 08.45 CET   Mauri Visuri that has been the Chairman of the Board since 2011 and a board member since 2010 have decided to resign from the Board on March 23[rd], 2020. Vice Chairman of the Board Eeva-Liisa Virkkunen, that is suggested by the nominating committee as the Chairman of the Board at the Annual General Meeting on April 2[nd] 2020, now takes over as Chairman of the Board.  Stockholm March 24, 2020   Sotkamo Silver AB Paul Johnsson, CEOContact person Paul Johnsson, CEO of Sotkamo Silver AB, tel. +46 70 777 6976

Nordic Capital increases its shareholding in Norwegian Finans Holding ASA

Nordic Capital Fund IX (“Nordic Capital”) has, through its wholly owned subsidiary Cidron Xingu Limited, last night acquired 7,598,162 shares in Norwegian Finans Holding ASA (“Bank Norwegian”) from a group of sellers including Green 91 AS, a company owned by Lars Ola Kjos, at a price of NOK 35 per share. The acquisition was made to strengthen Nordic Capital’s position as the largest shareholder and following the transaction, the holding will amount to 30,646,498 shares, corresponding to 16.4% of the total shares outstanding. In total, Nordic Capital and Sampo collectively own 42,472,603

Asarina Pharma to release historic Phase IIb PMDD data on schedule

Asarina Pharma expects to release top-line results of its Phase IIb PMDD study on schedule at the end of April. Asarina Pharma’s other studies on menstrual migraine and Tourette syndrome also remain on track. The company’s digital R&D Day, on March 26, will detail four key metrics it will use to evaluate the efficacy of Sepranolone, the first dedicated treatment for PMDD, which affects 1-in-20 women of reproductive age worldwide.Asarina Pharma’s Phase IIb study into PMDD (premenstrual dysphoric disorder) was conducted in the UK, Germany, Poland and Sweden. Enrolment was completed late in

Vitrolife evaluates measures to temporarily reduce staff costs

Vitrolife has previously announced that the company estimates that there will be a significant negative effect on the second quarter due to the reduced demand associated with the Coronavirus outbreak. The company has evaluated the situation and, if appropriate, will use the support packages in the countries concerned to temporarily reduce staff costs.Vitrolife estimates that the Coronavirus outbreak will have a significant negative impact on the demand for IVF treatments during the second quarter. The company has evaluated the situation and, if appropriate, will use the support packages in

The Nomination Committee's proposal for the election of board members in BioArctic AB

Stockholm March 24, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Nomination Committee for BioArctic AB provides the following proposals for resolution at the annual general meeting on May 7, 2020 regarding the number of board members and the election of board members.   The Nomination Committee proposes that the board shall consist of eight members, without deputies.   The Nomination Committee proposes that Wenche Rolfsen, Ivar Verner, Lars Lannfelt, Pär Gellerfors, Hans Ekelund, Eugen Steiner and Mikael Smedeby be re-elected as board members and that

Proact extends partnership with Dell Technologies

Proact is now fully certified by Dell Technologies for the Dell VxRail product family. Proact is currently the only Dell Technologies partner in the Nordic region offering complete VxRail solutions, from solutions design, installation and deployment, to support and maintenance.VxRail by Dell Technologies is a hyper-converged infrastructure solution, a type of system which integrates multiple data centre devices into a single, compact unit. The new certification testifies to Proact’s expertise in designing and delivering modern data centre solutions and reinforces the partnership with Dell

Yemen: Five years of war cripple coronavirus preparedness

· Civilian casualties spike again in deadly escalationFive years of war has crippled Yemen’s ability to prepare and face a possible outbreak of coronavirus, leaving millions extremely vulnerable under a decimated health system. Although Yemen does not have any confirmed COVID-19 cases as yet, the Norwegian Refugee Council is extremely concerned that any outbreak could have catastrophic consequences for displaced families. Five years of war have damaged and destroyed thousands of hospitals, and water and sanitation systems have collapsed. Yemen is already reeling from the impact of other

Herantis Pharma Plc announces Capital Markets Day webcast and provides update on business operations during COVID-19

Company will hold will hold a Capital Markets Day webcast on 24 March 2020 at 11:00 AM CET Business operations including ongoing clinical trials and preparation for future studies continue as plannedHerantis Pharma PlcPress release 24 March 2020 at 9:00 AM Eastern European Time   Herantis Pharma Plc (“Herantis” or “Company”) announced today that a Capital Markets Day will be held through a webcast. In addition the Company provided  an update on its business operations during the COVID-19 (coronavirus) pandemic. Herantis’ drug development pipeline currently has two active

MPC Container Ships Invest B.V. publishes FY 2019 Annual Report

Oslo/Rhoon, 24 March 2019 - MPC Container Ships Invest B.V. (the "Company", together with its subsidiaries the "Group") today published its Annual Report for the twelve-month period ended 31 December 2019. The Group reported a net loss of USD 25.9 million for FY 2019 (FY 2018: net loss of USD 3.1 million). The Annual Report has been filed with the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) and the Oslo Stock Exchange, and is available on the Company’s website: www.mpc-container.com. As at 31 December 2019, the Group has acquired and operates 39 container

Edgeware adds automated QoE optimization to its multi-CDN control platform StreamPilot

Broadcasters and content providers will benefit from unified view and automated problem mitigation to optimize QoE when delivering content in multi-CDN environmentsStockholm, Sweden – March 24, 2020 – Edgeware  has today announced the addition of its automated optimization capability to its multi-CDN control  platform StreamPilot . Referred to as AutoPilot, the feature gives broadcasters and content providers the option to automatically perform actions triggered by

Kungsleden stable in times of turbulence

Due to the turbulence now prevalent in the business sector and financial markets in connection with the spread of COVID-19, Kungsleden wants to clarify the following. Kungsleden is standing stable financially and in terms of our customer base.Kungsleden’s equity/assets ratio amounted to 44 per cent at year-end and the loan-to-value ratio was 45.8 per cent. We have no bond or bank loan maturities in 2020. At the same time, we have cash and facilities available to be able to manage all remaining maturities in the capital market in 2021.  “Kungsleden has built up a strong balance sheet and

TietoEVRY cancels Annual General Meeting and convenes a new meeting later

TietoEVRY Corporation        Stock Exchange Release        24 March 2020, 8.00 am  EET   Due to the coronavirus pandemic and measures set to ensure the safety and wellbeing of employees and other stakeholders, the Board of Directors of TietoEVRY Corporation has decided to cancel the Annual General Meeting scheduled to be held on Thursday 26 March 2020.   TietoEVRY intends to arrange the new meeting by the end of April and facilitate the shareholders’ possibilities to follow the general meeting through a live webcast and exercise their voting rights by using the proxy service

The Lancet Haematology Publishes Results from Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)

Stockholm — March 24, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM), a multicenter, international, open-label, phase 1/2 study in The Lancet Haematology 30044-2/fulltext). Melflufen is a first-in-class anti-cancer peptide-drug conjugate currently in development by Oncopeptides with activity in a variety of cancers. Current clinical development is focused on the treatment of RRMM.In

Axactor SE – Operational and financial update

Oslo, 23 March 2020  The coronavirus outbreak and the Government measures to limit the spreading of the virus have created an extraordinary situation for people, organizations and businesses in affected areas. Axactor hereby provides an update of the operational and financial implications. Axactor acts responsibly and in compliance with rules and recommendations from national and local authorities in all the six countries with operations, both to protect its employees and their families and local communities, and to ensure that the company remains operational for its customers,

Moberg Pharma enters financing agreement of up to SEK 216 million for further investments in MOB-015

STOCKHOLM, March 23[rd], 2020 - Moberg Pharma AB (publ) announces today that the company has entered into a convertible note agreement with Nice & Green S.A. (“N&G”), contingent on an authorization at an Extraordinary General Meeting. In December 2019, the company reported that the primary endpoint for MOB-015 was met in the North American phase 3 study. The evaluation of the study results showed that the rapid and high antifungal effect of MOB-015 is world leading, but that dosing may be optimized. Based on these data, MOB-015 has the potential to become the future market leader in

Acquisitions of own shares in Betsson AB and resolution on continuous acquisitions of own shares by way of an automated repurchase program

The board of directors of Betsson AB has, based on the authorisation from the annual general meeting held on 7 May 2019, resolved on acquisitions of own shares on Nasdaq Stockholm. The purpose of the acquisitions is to improve the capital structure of the company by reducing the capital.On 20 March 2020, Betsson AB disclosed acquisitions of a maximum of 2 million shares for a maximum value of SEK 60 million. As a result hereof, 1 033 148 shares have been acquired for a total price of SEK 33 959 260. The repurchase program is now intended to continue by way of a so-called automated

The Annual General Meeting of Ratos AB - Changes in the proposed dividend

Due to the situation with COVID-19, the Board of Directors proposes a dividend of SEK 0.30 per share, which differs from SEK 0.65 per share, which was previously communicated. However, the Board's ambition is to call the shareholders to an Extraordinary General Meeting later in the year to decide on a further dividend, if the market has stabilized at this time and the company's visibility in earnings has normalized.Amendments to the Board's proposal regarding dividend and record date (Item 11):  The Board of Directors has previously proposed, in the notice of the Annual General Meeting

SpagoPix phase I study to next dose level and expansion to additional site

Data from the first dose group in the phase I trial show that SN132D is well tolerated, and provide valuable information for optimization of MRI in the next step. Now that the study continues into the next dose level the company intend to up the pace in patient recruitment by engaging an additional study center.The internal safety review committee (iSRC) has analysed data of the first six patients of the clinical study SPAGOPIX-01 and concluded that the initial dose of SN132D is safe. The iSRC further conclude that the dose should be increased in order to optimize contrast enhancement of

There are no items matching the current filter
There are no more items matching the current filter
Back to top